Protalix BioTherapeutics (PLX) Non Operating Income (2012 - 2026)
Protalix BioTherapeutics' quarterly Non Operating Income came in at -$5000.0 in Q1 2026, down 101.21% year-on-year from $413000.0 in Q1 2025, and up 95.76% quarter-over-quarter from -$118000.0 in Q4 2025.
Protalix BioTherapeutics has reported Non Operating Income for 15 years, with the latest figure at -$5000.0 in Q1 2026.
- For the quarter ending Q1 2026, Non Operating Income fell 101.21% year-over-year to -$5000.0; the trailing twelve-month figure through Mar 2026 stood at -$526000.0 (down 199.81% YoY), and the FY2025 full-year result was -$108000.0, down 145.57% from the prior year.
- Non Operating Income for Q1 2026 stood at -$5000.0, up from -$118000.0 in the prior quarter.
- The five-year high for Non Operating Income was $413000.0 in Q1 2025, with the low at -$811000.0 in Q4 2023.
- Average Non Operating Income over 5 years is -$185470.6, with a median of -$118000.0 recorded in 2025.
- Year-over-year, Non Operating Income plunged 507.37% in 2023 and surged 235.77% in 2025.
- Tracing PLX's Non Operating Income over 5 years: stood at -$715000.0 in 2022, then fell by 13.43% to -$811000.0 in 2023, then jumped by 113.19% to $107000.0 in 2024, then plunged by 210.28% to -$118000.0 in 2025, then jumped by 95.76% to -$5000.0 in 2026.
- The last three Non Operating Income figures came in at -$5000.0 (Q1 2026), -$118000.0 (Q4 2025), and $108000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn | -5,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5,000.00 |
| Dec 31, 2025 | -118,000.00 |
| Sep 30, 2025 | 108,000.00 |
| Jun 30, 2025 | -511,000.00 |
| Mar 31, 2025 | 413,000.00 |
| Dec 31, 2024 | 107,000.00 |
| Sep 30, 2024 | -148,000.00 |
| Jun 30, 2024 | 155,000.00 |
| Mar 31, 2024 | 123,000.00 |
| Dec 31, 2023 | -811,000.00 |
| Sep 30, 2023 | 168,000.00 |
| Jun 30, 2023 | -774,000.00 |
| Mar 31, 2023 | -477,000.00 |
| Dec 31, 2022 | -715,000.00 |
| Sep 30, 2022 | -442,000.00 |
| Jun 30, 2022 | 190,000.00 |
| Mar 31, 2022 | -416,000.00 |
| Dec 31, 2021 | -910,000.00 |
| Sep 30, 2021 | -2.31 Mn |
| Jun 30, 2021 | -2.08 Mn |
| Mar 31, 2021 | -1.82 Mn |
| Dec 31, 2020 | -2.44 Mn |
| Sep 30, 2020 | -1.86 Mn |
| Jun 30, 2020 | -1.91 Mn |
| Mar 31, 2020 | -3.03 Mn |
| Dec 31, 2019 | -1.91 Mn |
| Sep 30, 2019 | -2.02 Mn |
| Jun 30, 2019 | -1.90 Mn |
| Mar 31, 2019 | -1.73 Mn |
| Dec 31, 2018 | -1.76 Mn |
| Sep 30, 2018 | -1.58 Mn |
| Jun 30, 2018 | -1.72 Mn |
| Mar 31, 2018 | -2.09 Mn |
| Dec 31, 2017 | -3.72 Mn |
| Sep 30, 2017 | -3.67 Mn |
| Jun 30, 2017 | 11.26 Mn |
| Mar 31, 2017 | -52.78 Mn |
| Dec 31, 2016 | 6.10 Mn |
| Sep 30, 2016 | -642,000.00 |
| Jun 30, 2016 | -805,000.00 |
| Mar 31, 2016 | -662,000.00 |
| Dec 31, 2015 | -871,000.00 |
| Sep 30, 2015 | -1.01 Mn |
| Jun 30, 2015 | -599,000.00 |
| Mar 31, 2015 | -1.13 Mn |
| Mar 31, 2014 | -877,000.00 |
| Dec 31, 2013 | -737,000.00 |
| Sep 30, 2013 | -102,000.00 |
| Jun 30, 2013 | 57,000.00 |
| Mar 31, 2013 | 108,000.00 |
| Dec 31, 2012 | 290,000.00 |
| Sep 30, 2012 | 81,000.00 |
| Jun 30, 2012 | 22,000.00 |